Literature DB >> 29629407

New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?

Ron Balkissoon1.   

Abstract

Year:  2018        PMID： 29629407      PMCID： PMC5870743          DOI： 10.15326/jcopdf.5.1.2018.0128

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  23 in total

1.  Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.

Authors:  Neil C Barnes; Raj Sharma; Sally Lettis; Peter M A Calverley
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

2.  A Light in the Darkness? The FLAME Trial, Blood Eosinophils, and Chronic Obstructive Pulmonary Disease.

Authors:  Peter M A Calverley
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

3.  Pharmacological treatment for COPD; GOLD 2017 changes direction.

Authors:  Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2017-03-09       Impact factor: 4.335

4.  A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.

Authors:  Steven J Pascoe; David A Lipson; Nicholas Locantore; Helen Barnacle; Noushin Brealey; Rajat Mohindra; Mark T Dransfield; Ian Pavord; Neil Barnes
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

5.  Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

Authors:  Courtney Crim; Peter M A Calverley; Julie A Anderson; Andrew P Holmes; Sally Kilbride; Fernando J Martinez; Robert D Brook; David E Newby; Julie C Yates; Bartolomé R Celli; Jørgen Vestbo
Journal:  Respir Med       Date:  2017-08-01       Impact factor: 3.415

6.  Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.

Authors:  Jadwiga A Wedzicha; Alvar Agusti; Gavin Donaldson; Ferran Chuecos; Rosa Lamarca; Esther Garcia Gil
Journal:  COPD       Date:  2016-05-09       Impact factor: 2.409

7.  Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma.

Authors:  Umme Kolsum; Arjun Ravi; Paul Hitchen; Satyanarayana Maddi; Thomas Southworth; Dave Singh
Journal:  Respir Res       Date:  2017-04-26

8.  Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.

Authors:  Dave Singh; Mina Gaga; Olaf Schmidt; Leif Bjermer; Lars Grönke; Florian Voß; Gary T Ferguson
Journal:  Respir Res       Date:  2016-06-18

9.  Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.

Authors:  Dave Singh; M Reza Maleki-Yazdi; Lee Tombs; Ahmar Iqbal; William A Fahy; Ian Naya
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-24

10.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Authors:  Ian D Pavord; Sally Lettis; Nicholas Locantore; Steve Pascoe; Paul W Jones; Jadwiga A Wedzicha; Neil C Barnes
Journal:  Thorax       Date:  2015-11-19       Impact factor: 9.139
View more
  1 in total

Review 1.  Targeting IL-5 in COPD.

Authors:  Dharani K Narendra; Nicola A Hanania
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.